CTOs on the Move

Ideaya Biosciences

www.ideayabio.com

 
IDEAYA Biosciences is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. Founded in 2015, IDEAYA`s investors include 5AM Ventures (5AM), Canaan Partners (Canaan), Celgene, WuXi Healthcare Ventures (WuXi), Novartis Institute of Biomedical Research, and Alexandria Real Estate. The Company has assembled a world-class drug discovery team and Scientific Advisory Board (SAB) that is represented by a Nobel Laureate and three Members of the National Academy of Sciences. IDEAYA is located in South San Francisco and La Jolla, California.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.ideayabio.com
  • 7000 Shoreline Court Suite 350
    South San Francisco, CA USA 94080
  • Phone: 650.443.6209

Executives

Name Title Contact Details
Solomon Wang
 Director, IT Profile

Funding

Ideaya Biosciences raised $94M on 03/15/2018
Ideaya Biosciences raised $86.1M on 07/07/2021

Similar Companies

ViaCyte

ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte`s product candidates are based on directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, which are then implanted in durable and retrievable cell delivery devices. ViaCyte demonstrated that when effectively engrafted, PEC-01 cells can mature into glucose-responsive insulin producing cells in patients with type 1 diabetes. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with leading companies including CRISPR Therapeutics and W.L. Gore & Associates.

Oncology Plus

Oncology Plus is a Brandon, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Amarantus

Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. The Company has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready indication for Parkinson's Levodopa induced dyskinesia and Adult ADHD. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test(R)") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders.   Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard").

Labquip

Labquip Ltd is a Woodbridge, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Brijen Biotech

Brijen Biotech is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.